Jazz Pharmaceuticals Q3 revenue beats estimates

Jazz Pharmaceuticals

05/11/2025 21:14

Overview

Jazz Pharmaceuticals Q3 revenue grows 7% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting robust operational performance

Company narrows 2025 revenue guidance to $4.175 - $4.275 bln

Outlook

Company narrows 2025 revenue guidance to $4.175 - $4.275 bln

Jazz Pharmaceuticals expects top-line data from zanidatamab trial in 4Q25

Result Drivers

EPIDIOLEX AND XYWAV GROWTH - Epidiolex and Xywav sales saw double-digit percentage growth, driven by increased demand and lower gross to net deductions

MODEYSO LAUNCH - Modeyso launched commercially in August 2025 with strong initial uptake, generating $11 mln in sales

ZEPZELCA APPROVAL - Zepzelca and atezolizumab combination approved for 1L maintenance therapy in ES-SCLC, though Zepzelca sales decreased

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$1.13 bln
$1.11 bln (16 Analysts)
Q3 Adjusted EPS
Beat
$8.13
$5.92 (15 Analysts)
Q3 EPS
$4.08
Q3 Adjusted Net Income
Beat
$500.65 mln
$368.64 mln (15 Analysts)
Q3 Net Income
$251.41 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $185.00, about 25.5% above its November 4 closing price of $137.82

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nPre6DpHMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)